MDWD
MediWound Ltd.
Biotechnology
Market Cap$222M
5Y Perf.-6.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MDWD vs SLXN
Revenue, margins, valuation, and 5-year total return — side by side.
SLXN
Silexion Therapeutics Ltd.
Biotechnology
Market Cap$2M
5Y Perf.-99.7%
MDWD vs SLXN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MDWD | SLXN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $222M | $2M |
| Revenue (TTM) | $17M | $0.00 |
| Net Income (TTM) | $-24M | $-12M |
| Gross Margin | 19.2% | — |
| Operating Margin | -149.1% | — |
| Total Debt | $9M | $468K |
| Cash & Equiv. | $5M | $6M |
MDWD vs SLXN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MDWD
SLXN
| Stock | Aug 24 | May 26 | Return |
|---|---|---|---|
| MediWound Ltd. (MDWD) | 100 | 93.9 | -6.1% |
| Silexion Therapeuti… (SLXN) | 100 | 0.3 | -99.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MDWD vs SLXN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MDWD leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Silexion Therapeutics Ltd. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
MDWD
MediWound Ltd.
The Income Pick
MDWD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.13
- Rev growth -16.1%, EPS growth 30.7%, 3Y rev CAGR -13.8%
- -68.4% 10Y total return vs SLXN's -99.8%
Best for: income & stability and growth exposure
SLXN
Silexion Therapeutics Ltd.
The Growth Leader
SLXN is the clearest fit if your priority is growth and quality.
- 19.0% revenue growth vs MDWD's -16.1%
- 2.0% margin vs MDWD's -140.8%
Best for: growth and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SLXN | 19.0% revenue growth vs MDWD's -16.1% |
| Quality / Margins | SLXN | 2.0% margin vs MDWD's -140.8% |
| Stability / Safety | MDWD | Beta 1.13 vs SLXN's 2.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MDWD | -3.3% vs SLXN's -96.5% |
| Efficiency (ROA) | MDWD | -30.2% ROA vs SLXN's -144.7% |
MDWD vs SLXN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMDWDLAGGINGSLXN
SLXNSilexion Therapeutics…
0leads
MDWDMediWound Ltd.
3leads
6 Total Categories
CATEGORYLEADERvs SLXNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MDWD1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
MDWD6/6
Risk & VolatilityBeta, volatility, and downside exposure
MDWD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MDWD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MDWD and SLXN operate at a comparable scale, with $17M and $0 in trailing revenue.
| Metric | MDWDMediWound Ltd. | SLXNSilexion Therapeu… |
|---|---|---|
| RevenueTrailing 12 months | $17M | $0 |
| EBITDAEarnings before interest/tax | -$23M | -$12M |
| Net IncomeAfter-tax profit | -$24M | -$12M |
| Free Cash FlowCash after capex | -$21M | -$11M |
| Gross MarginGross profit ÷ Revenue | +19.2% | — |
| Operating MarginEBIT ÷ Revenue | -149.1% | — |
| Net MarginNet income ÷ Revenue | -140.8% | — |
| FCF MarginFCF ÷ Revenue | -122.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -68.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -55.6% | -6.4% |
MDWD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MDWD and SLXN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MDWDMediWound Ltd. | SLXNSilexion Therapeu… |
|---|---|---|
| Market CapShares × price | $222M | $2M |
| Enterprise ValueMkt cap + debt − cash | $226M | -$4M |
| Trailing P/EPrice ÷ TTM EPS | -8.22x | -0.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 13.07x | — |
| Price / BookPrice ÷ Book value/share | 4.50x | 0.27x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MDWD and SLXN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — MDWD and SLXN each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
MDWD delivers a -65.8% return on equity — every $100 of shareholder capital generates $-66 in annual profit, vs $-4 for SLXN. SLXN carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDWD's 0.20x. On the Piotroski fundamental quality scale (0–9), SLXN scores 5/9 vs MDWD's 4/9, reflecting solid financial health.
| Metric | MDWDMediWound Ltd. | SLXNSilexion Therapeu… |
|---|---|---|
| ROE (TTM)Return on equity | -65.8% | -3.9% |
| ROA (TTM)Return on assets | -30.2% | -144.7% |
| ROICReturn on invested capital | -49.5% | — |
| ROCEReturn on capital employed | -47.0% | -6.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.20x | 0.18x |
| Net DebtTotal debt minus cash | $4M | -$6M |
| Cash & Equiv.Liquid assets | $5M | $6M |
| Total DebtShort + long-term debt | $9M | $468,000 |
| Interest CoverageEBIT ÷ Interest expense | -2.05x | -1321.56x |
Evenly matched — MDWD and SLXN each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MDWD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MDWD five years ago would be worth $5,519 today (with dividends reinvested), compared to $20 for SLXN. Over the past 12 months, MDWD leads with a -3.3% total return vs SLXN's -96.5%. The 3-year compound annual growth rate (CAGR) favors MDWD at 17.7% vs SLXN's -87.5% — a key indicator of consistent wealth creation.
| Metric | MDWDMediWound Ltd. | SLXNSilexion Therapeu… |
|---|---|---|
| YTD ReturnYear-to-date | -6.2% | -72.4% |
| 1-Year ReturnPast 12 months | -3.3% | -96.5% |
| 3-Year ReturnCumulative with dividends | +62.9% | -99.8% |
| 5-Year ReturnCumulative with dividends | -44.8% | -99.8% |
| 10-Year ReturnCumulative with dividends | -68.4% | -99.8% |
| CAGR (3Y)Annualised 3-year return | +17.7% | -87.5% |
MDWD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
MDWD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MDWD is the less volatile stock with a 1.13 beta — it tends to amplify market swings less than SLXN's 2.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MDWD currently trades 76.7% from its 52-week high vs SLXN's 2.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MDWDMediWound Ltd. | SLXNSilexion Therapeu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.13x | 2.26x |
| 52-Week HighHighest price in past year | $22.51 | $22.36 |
| 52-Week LowLowest price in past year | $14.90 | $0.52 |
| % of 52W HighCurrent price vs 52-week peak | +76.7% | +2.3% |
| RSI (14)Momentum oscillator 0–100 | 55.2 | 22.5 |
| Avg Volume (50D)Average daily shares traded | 83K | 68K |
MDWD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MDWDMediWound Ltd. | SLXNSilexion Therapeu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $36.00 | — |
| # AnalystsCovering analysts | 13 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MDWD leads in 3 of 6 categories — strongest in Income & Cash Flow and Total Returns. 2 categories are tied.
Best OverallMediWound Ltd. (MDWD)Leads 3 of 6 categories
Loading custom metrics...
MDWD vs SLXN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MDWD or SLXN a better buy right now?
Analysts rate MediWound Ltd.
(MDWD) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MDWD or SLXN?
Over the past 5 years, MediWound Ltd.
(MDWD) delivered a total return of -44. 8%, compared to -99. 8% for Silexion Therapeutics Ltd. (SLXN). Over 10 years, the gap is even starker: MDWD returned -68. 4% versus SLXN's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MDWD or SLXN?
By beta (market sensitivity over 5 years), MediWound Ltd.
(MDWD) is the lower-risk stock at 1. 13β versus Silexion Therapeutics Ltd. 's 2. 26β — meaning SLXN is approximately 100% more volatile than MDWD relative to the S&P 500. On balance sheet safety, Silexion Therapeutics Ltd. (SLXN) carries a lower debt/equity ratio of 18% versus 20% for MediWound Ltd. — giving it more financial flexibility in a downturn.
04Which is growing faster — MDWD or SLXN?
On earnings-per-share growth, the picture is similar: MediWound Ltd.
grew EPS 30. 7% year-over-year, compared to -239. 4% for Silexion Therapeutics Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MDWD or SLXN?
Silexion Therapeutics Ltd.
(SLXN) is the more profitable company, earning 0. 0% net margin versus -140. 8% for MediWound Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLXN leads at 0. 0% versus -149. 1% for MDWD. At the gross margin level — before operating expenses — MDWD leads at 12. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MDWD or SLXN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MDWD or SLXN better for a retirement portfolio?
For long-horizon retirement investors, MediWound Ltd.
(MDWD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13)). Silexion Therapeutics Ltd. (SLXN) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDWD: -68. 4%, SLXN: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MDWD and SLXN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.